38608-07-0

Usage

Uses

Used in Pharmaceutical Development:
1,2-Diamino-4,5-methylenedioxybenzene, dihydrochloride is used as a key component in the development of novel drugs and pharmaceuticals due to its ability to effectively interact with biological systems. Its strong antioxidant and anti-inflammatory properties make it a promising candidate for the treatment of various diseases and conditions.
Used in Medical Treatments:
In the medical field, 1,2-Diamino-4,5-methylenedioxybenzene, dihydrochloride is utilized as a therapeutic agent for its potential to combat oxidative stress and inflammation, which are common factors in numerous diseases.
Used in Dye Synthesis:
1,2-Diamino-4,5-methylenedioxybenzene, dihydrochloride is employed as a precursor in the synthesis of dyes, leveraging its chemical structure to create a variety of colorants for different applications.
Used in Materials Science:
In materials science, 1,2-Diamino-4,5-methylenedioxybenzene, dihydrochloride is used as a component in the development of new materials, taking advantage of its chemical properties to enhance material performance and create innovative products.

InChI:InChI=1/C7H8N2O2/c8-4-1-6-7(2-5(4)9)11-3-10-6/h1-2H,3,8-9H2

Upstream product

• 274-09-9 Methylenedioxybenzene 
• 2620-44-2 5-nitro-1,3-benzodioxole 
• 7748-59-6 5,6-dinitro-benzo[1,3]dioxole 
• 102-51-2 4-methoxy-1,2-phenylenediamine 

Downstream Products

• 35541-25-4 2-Mercapto-5,6-methylendioxy-benzimidazol 

Relevant academic research and scientific papers

HETEROCYCLIC LSF INHIBITORS AND THEIR USES

The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used

Class of large ring heterocyclic compound restraining HCV and manufacturing and uses thereof

The invention relates to a class of compounds that inhibit HCV. The compounds are represented by Formula A. The invention also relates to preparation and pharmaceutical use of the compounds.

Benzimidazole compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

Inhibitors or bone reabsorption and antagonists of vitronectin receptors

Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation a

Structure-activity relationships of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor

We report on a series of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones (QXs), prepared as a continuation of our structure-activity relationship (SAR) study of QXs as antagonists for the glycine site of the N-methyl-D-aspartate (NMDA) re